The board of directors of Hi-Tech Pharmacal Co., Inc. (HITK) announced that it had entered into a definitive merger agreement to be acquired by Akorn, Inc. The proposed transaction values Hi-Tech Pharmacal at roughly $640 million. Under the terms of the agreement, public shareholders of Hi-Tech will receive $43.50 per share in cash for each share of Hi-Tech they own.
If you own the common stock of Hi-Tech Pharmacal and are concerned about the transaction and would like to learn more about how to begin a cost free corporate review of this merger, please fill out the contact form on this web page or call Attorney George Pressly at 1-(800)-631-6234.
State security laws provide shareholders a no cost means to question a proposed sale of a publicly traded company. This review process is deemed a shareholder class action and affords at times shareholders an avenue to investigate fully the proposed transaction. At minimum, this process often obtains answers to the above questions. If you own the common stock of Hi-Tech Pharmacal and if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please fill out the contact form on this web page.